Podcasts about veeva

Veeva's VP of Strategy, Bree Burks, reveals the strategic vision behind their groundbreaking free CTMS platform—a bold move designed to democratize technology access for clinical research sites of all sizes. Discover why Veeva prioritizes site success through standardization and simplicity, and how selecting the right technology partnerships can empower sites to scale operations and thrive.

Im letzten Jahr hatten wir bereits zum Thema Medical Affairs gesprochen. Warum ist das Thema wichtig für Pharma, wenn es um Effizienz und Patientenversorgung geht? Das fragen wir nach, wieder bei Christoph Bug, VP Global Medical, Veeva.

In this episode, CJ is joined by Peter Benevides, CFO of Olo, a leading vertical SaaS company powering digital ordering, payments, and guest engagement solutions for popular restaurant brands. Peter explains how Olo successfully expanded into payments and used this as a strategic advantage. He breaks down how the company stacks S-curves through continued product expansion and adoption, and how this enables them to increase revenue without increasing the take-rate. The conversation also covers pricing strategy and how Olo balances subscription and consumption-based models. Peter also sheds light on what it's like selling into franchise businesses and lessons learned from other vertical SaaS companies like Veeva.If you're looking for an ERP head to NetSuite: https://netsuite.com/metrics and get a customized KPI checklist.—SPONSORS:NetSuite provides financial software for all your business needs. More than 40,000 companies have already upgraded to NetSuite, gaining visibility and control over their financials, inventory, HR, eCommerce, and more. If you're looking for an ERP platform ✅, head to NetSuite https://netsuite.com/metrics and get the CFO's Guide to AI and Machine Learning.RightRev automates the revenue recognition process from end to end, gives you real-time insights, and ensures ASC 606 / IFRS 15 compliance—all while closing books faster. Whether it's multi-element arrangements, subscription renewals, or complex usage-based contracts, RightRev takes care of it all. That means fewer spreadsheets, fewer errors, and more time for your team to focus on growth. For modern revenue recognition simplified, visit rightrev.com and schedule a demo.Planful is a financial performance management platform designed to streamline financial tasks for businesses. It helps with budgeting, closing the books, and financial reporting, all on a cloud-based platform. By improving the efficiency and accuracy of these processes, Planful allows businesses to make better financial decisions. Find out more at www.planful.com/metrics.Brex offers the world's smartest corporate card on a full-stack global platform that is everything CFOs need to manage their finances on an elite level. Plus they offer modern banking and treasury as well as intuitive expenses and accounting automation, bill pay, and travel. Brex makes it easy to control spend before it happens, automate annoying tasks, and optimize your finances. Find out how Brex can help you make every dollar count at brex.com/metrics.Vanta's trust management platform takes the manual work out of your security and compliance process and replaces it with continuous automation. Over 9000 businesses use it to automate compliance needs across over 35 frameworks like SOC 2 and ISO 27001. Centralize security workflows, complete questionnaires up to five times faster, and proactively manage vendor risk. For a limited time, get $1,000 off of Vanta at vanta.com/metrics.Tropic is an intelligent spend management solution that consolidates your spend data and processes into one unified offering, enabling insights and decisive action. It doesn't just show you where the problems are—it helps you solve them. From spotting hidden optimization opportunities, like duplicative spend, to automating those painful procurement workflows, to giving you the best market data that turns every vendor negotiation in your favor. Tropic combines smart insights with real human expertise to keep you ahead of the curve. Visit tropicapp.io/mostlymetrics to learn how—FOLLOW US ON X:@cjgustafson222 (CJ)—TIMESTAMPS:(00:00) Preview and Intro(01:53) Sponsor – NetSuite | RightRev | Planful(05:24) An Introduction to Olo(08:34) Reaching Larger and Smaller Enterprises(10:34) The Focus on Guest-Facing Technology(13:22) The Evolution of Payments at Olo(16:38) Sponsor – Brex | Vanta | Tropic(20:33) The Card-Not-Present Offering and Fraud(23:50) Knowing Who Your Guest Is and Olo's Extended Value Prop(32:04) Stacking S-Curves(33:30) Increasing Revenue Without Increasing the Take-Rate(36:27) How the Payments Module Makes Other Products Stickier(37:39) Advice to CFOs Looking to Add Payments(39:11) Pricing Subscription and Consumption-Based Products(42:35) Forecasting and the Predictability of This Model(44:43) Vertical Software Company Case Study: Veeva(49:06) Working with Franchises(53:42) Long-Ass Lightning Round: Planning for the Future(56:16) Advice to Younger Self(58:48) Finance Software Stack(59:24) Craziest Expense Story Get full access to Mostly metrics at www.mostlymetrics.com/subscribe

Jake Saper is a General Partner @ Emergence Capital, one of the leading venture firms of the last 20 years. Their many wins include being early investors in Salesforce, Zoom, Veeva and more. In total, the firm has invested $2BN and returned an astonishing $8BN in cash with much more to come.  In Today's Episode We Discuss: 04:45 The Zoom Investment Story 10:21 Founder, Market, Traction: Rank Them 26:37 Why Market Pull is the Most Important Thing and How to Know 27:23 Are the Best Deals Always Expensive? 28:25 What is the One Framework Emergence Use for Every Investment 29:08 Lessons from the 16x DPI Zoom Fund 30:44 Why Does Every Partner Do Reference Calls on Every Deal? 35:16 We Have Lied to SaaS Founders: The Revenue Rules Changed 37:53 Where Will Value Accrue in a World of AI?  41:37 Three Reasons Why AI Will Not Replace Vertical SaaS 46:38 Who Wins in AI: Startups or Incumbents? 50:09 Why Should Every Company Aim to Be a “Board Discussion” 55:12 Why is Jake Worried About AI's FTX Moment? 56:00 What Losing Billions on Salesforce Taught Us About Selling 01:00:07 Why Most VC Partnerships are Broken 01:03:07 Grok vs Anthropic vs OpenAI: Buy and Sell? 01:14:25 Quickfire Round: Insights and Reflections  

Ce vendredi x mois année, Liste INVITES et FONCTiON, se sont penchés sur les titres (....à lister... ), dans On achète ou on vend ? dans l'émission C'est Votre Argent présentée par Marc Fiorentino. C'est Votre Argent est à voir ou écouter le vendredi sur B

Aktien hören ist gut. Aktien kaufen ist besser. Bei unserem Partner Scalable Capital geht's unbegrenzt per Trading-Flatrate oder regelmäßig per Sparplan. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen. Nissan & Honda peilen 2026 an. Toyota peilt 20% an. Apple peilt Videotürklingel an. Lockheed & Co. kriegen Konkurrenz von Jungen. Veeva kriegt Konkurrenz von Salesforce. MicroStrategy kauft weiter. Achja: Lilium, Delivery & Rumble haben Investor-News. KI zerstört repetitive Aufgaben. Aber bis es soweit ist, verdient TaskUs (WKN: A3CR4H) mit ihnen Milliarden. Hyperscaler wie Amazon oder Alphabet hatten mal wieder ein super Jahr. Viele sind optimistisch, dass das so weitergeht. Der Investor Josh Wolfe sieht das anders. Er setzt auf Micron (WKN: 869020), SK Hynix (WKN: A1JWRE) und Samsung (WKN: 881823). Diesen Podcast vom 27.12.2024, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

In this podcast, we explore how digitally active HCPs and emerging experts can amplify the impact of scientific data presented at congresses to drive successful drug launches. Industry experts from Pfizer and Veeva discuss strategies for engaging these key influencers to optimize launch success.

Veeva Systems (NYSE: VEEV) is helping pharmaceutical companies create and sell new drugs more efficiently. It's cloud-based software platforms Veeva CRM and Veeva Vault have become industry-standards; deeply embedded with Big Pharma's largest companies. There's an upcoming catalyst next year, as Veeva's CRM platform will migrate from being hosted by Salesforce to its own infrastructure. That will unlock opportunities for it to develop new software products -- perhaps even beyond life sciences -- to make the pie larger with its largest customers. As interest rates fall, it's likely new VC funding will flow into smaller biotech companies and will unlock a new SMB revenue stream as well. 7investing CEO Simon Erickson describes both of these catalysts, as well as why he believes the stock is undervalued, in today's 7investing podcast. To see all of our official stock recommendations and our monthly Best Buys, get started with 7investing at ⁠7investing.com/subscribe⁠. Your first week of our premium membership is entirely free!

In this episode, Geert van Kempen, Head of Food and Beverage Strategy at Veeva Systems, shares his expertise on digital transformation in the food and beverage industry. He discusses Veeva's innovative cloud-based software solutions that address food safety management, HACCP, efficiency, compliance, and sustainability. With a background in life sciences and food/beverage, Geert provides valuable insights into the industry's challenges and opportunities. Tune in to learn how Veeva's solutions are transforming the industry and gain expert advice on navigating the evolving food and beverage landscape.

Two years after the announcement that Veeva and Salesforce would part ways, Life Sciences organizations are racing to evaluate their options and select their CRM partner before the 2025 cutover. Jen is joined by Vynamic's Life Sciences Commercial Operations Lead, Jeremy Shirey, and Tech & Digital Transformation Service Lead, Vince Annerhed-Harris as well as special guests, CodeScience's CEO, Mike Utell, and Chief Revenue Officer, Sean Hogan, to discuss how Life Sciences leaders should approach this decision and transition to minimize disruption and maximize business value.For more information about CodeScience, visit their website: https://www.codescience.com/For more information about Vynamic's work in Commercial Operations and Tech & Digital Transformation, visit: https://vynamic.com/ Podcast Tags: healthcare, life sciences, healthcare technology, healthcare news, Veeva, Salesforce, tech and digital transformation, CRM, commercial operations, CodeSciencePanel – Jen Burke, Jeremy Shirey, Vince Annerhed-Harris, Mike Utell, Sean HoganResearch & Production – Jen Burke, Jeremy Shirey, Vince Annerhed-HarrisRecording & Editing – Mike Liberto, Rachel SkoneckiFor additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

日本のIT市場は約15兆円規模ですが、SaaSの占有率は10%未満です。エンタープライズ向けSaaS（エンプラSaaS）は成長余地が大きいものの、展開に苦戦する企業も多くみられます。エンプラSaaSの成功には、需要創出からポストセールスまで戦略の大幅な変更が必要で、その中でプロフェッショナルサービス（PS）の役割が重要となります。本セッションでは、Oracle、Salesforce、Veeva JapanにてPS経験豊富な大村さんをお迎えし、PSの定義や重要性、エンプラSaaSにおけるPSの必要性、採用・組織戦略について議論しました。 ハイライト 大村さんの約30年間に及ぶプロフェッショナルサービスのご経歴 大手ソフトウェア企業の日本市場はこの十数年間でどう変化してきたか Veeva Japanに入社された背景や決め手 プロフェッショナルサービスのミッションについて、業務内容はどのようなものか 受注から契約、導入支援などのフローの中で他の職種との連携について BPOやビジネスコンサルやカスタマーサクセス・サポートとの違いとは？ プロフェッショナルサービスの具体的なKPIについて PSの組織化や採用はどのように行っているか 入社後からのオンボーディングはどのようにプラン化されているか 大村耕平 Veeva Japan 株式会社　VP, Japan Commercial Professional Services 日本のプロフェッショナルサービス責任者である大村耕平は、ソフトウェアIT業界で約30年の勤務経験があり、顧客の業務改善や製品の有効活用促進するプロジェクトでプロジェクトオーナー、プロジェクトマネージャーとして多くの成功経験を持っています。Veeva入社前は、セールスフォースでMarketing Cloud製品のプロフェッショナルサービス執行役員として導入プロジェクトの責任を担っていました。また、セールスフォース以前は、日本オラクルにてミドルウェアコンサルティング、SaaSコンサルティング本部長としてサービスの提案から導入までの責任を持ち、お客様の成功と共にチームを成長させて来ました。

Explore the dynamic world of regulatory affairs with Amra Racic, a seasoned expert with over 25 years of experience with Medical Alley partners, including  Medtronic and Abbott. Now at Veeva Systems as Senior Director of Government Strategy, Amra brings her deep expertise to the Medical Alley Podcast, where she unpacks the complexities of navigating global regulatory requirements.In this episode, Amra shares invaluable insights on leadership and career development within regulatory affairs, highlighting the crucial roles of inclusivity, ethical decision-making, and mentoring. The discussion also tackles the vital issue of health equity in medical device regulation and underscores the importance of data transparency in achieving fair health outcomes for all.Send us a message!Follow Medical Alley on social media on LinkedIn, Facebook, Twitter and Instagram.

In this episode, you will learn about what type of insurance (if any) is needed to conduct a clinical trial. We also discuss different insurance provisions, choosing the right insurance partner, regulatory requirements that dictate insurance and much more. Dan is a seasoned insurance professional with 10+ years of underwriting and broking experience. Dan and his team also assist in the implementation of alternative risk mitigation strategies, and see themselves as strategic partners to those in the life science space. Dan graduated from the Katie School of Insurance at Illinois State University where he studied Risk Management and Enjoy! Sponsor(s): This podcast is brought to you by Calyx. Calyx is a trusted name in medical imaging, having delivered imaging services to meet the needs of global biopharmaceutical sponsors and clinical research organizations for over 25 years. To learn more, visit https://www.calyx.ai/ This podcast is brought to you by Veeva SiteVault. Veeva connects patients, sites, and sponsors, on a single technology ecosystem to make clinical trials easier and faster. SiteVault gives research sites one place to work with sponsors – to reduce the number of systems and logins used to run clinical trials. To learn more, visit ​https://sites.veeva.com/​  

In this podcast, we discuss a data-driven approach for optimizing congress planning and execution. MAPS speaks with experts from United Therapeutics and Veeva for tips on finding the right events, effectively engaging the right experts, and enabling medical teams to do more with less.

Uploaded by ⁠TDM Growth Partners

Instant analysis of Veeva Systems ($VEEV) Q1 earnings, as we hear from CEO Peter Gassner. More than “beat” or “miss” –the Drill Down Earnings with Futurum Group chief market strategist Cory Johnson has the business stories behind stocks on the move.    https://x.com/corytv #Veeva Systems #Earnings @Veeva Systems $VEEV #Technology #Software #CloudComputing #Chips #AI #ArtificialIntelligence #Semiconductors #Stocks #Trading #Business @DrillDownPod Learn more about your ad choices. Visit megaphone.fm/adchoices

For health systems, it's important to leverage all tools in the digital marketing toolkit to support digital patient experience efforts. In this episode, hosts Chris Boyer and Reed Smith discuss the role digital advertising plays in supporting online experiences and share ways to leverage UX/Ui to optimize advertising efforts. They are joined by Jeremy Mittler of Veeva who share how to develop a privacy-first advertising segmentation strategy.  Mentions from the show:  Digital Customer Experience: A Marketing Game Changer The Art of Patient-Targeted Advertising in Healthcare The Role of UI/UX in Advertising: Creating User-Centric Ad Campaigns Jeremy Mittler on LinkedIn Veeva.com Learn more about your ad choices. Visit megaphone.fm/adchoices

To learn more about clinical trials in diabetes, I invited Dr. Stayce Beck, Global Vice President of Clinical Affairs at Dexcom Inc. on the podcast.  Dr. Beck currently oversees clinical operations, clinical strategy and science, biometrics and human factors at Dexcom Inc, a leading manufacturer of continuous glucose monitors (CGMs) Prior to joining Dexcom, Dr. Beck worked at Food and Drug Administration for over ten years, spending time as a scientific and regulatory reviewer, a chief of the Diabetes Diagnostic Devices Branch, and Deputy Office Director of Personalized Medicine and Molecular Genetics. Dr. Beck received her Ph.D. in Biomedical Science from the University of California San Diego, and her B.S. in Chemical Engineering from the University of Texas at Austin.  She also received her Master of Public Health (MPH) in Epidemiology from University of Maryland Baltimore.  Sponsor(s): This podcast is brought to you by Calyx. Calyx is a trusted name in medical imaging, having delivered imaging services to meet the needs of global biopharmaceutical sponsors and clinical research organizations for over 25 years. To learn more, visit https://www.calyx.ai/ This podcast is brought to you by Veeva SiteVault. Veeva connects patients, sites, and sponsors, on a single technology ecosystem to make clinical trials easier and faster. SiteVault gives research sites one place to work with sponsors – to reduce the number of systems and logins used to run clinical trials. To learn more, visit ​https://sites.veeva.com/​.

Veeva Systems Inc. - Analyst/Investor Day

Veeva Systems Inc., Q3 2024 Earnings Call, Dec 06, 2023

Veeva Systems's Q3 2023 earnings call, unedited

This podcast reviews new ways of identifying and quantifying opportunities for field medical impact with disease-state analytics. Industry experts from Pfizer and Veeva discuss how longitudinal patient-level data can pave the way for a more patient-centric way of informing and shaping Medical Affairs strategy and operations.

Veeva Site Vault: https://sites.veeva.com/Versatrial: http://www.versatrial.ioCRIO: http://www.clinicalresearch.ioInato: https://go.inato.com/3VnSro61nHealth: https://1nhealth.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256My podcast is Random Musings From The Clinical Trials GuruListen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSferaLifeBoost Coffee: https://lifeboostcoffee.com/products/biotics-brew?_pos=2&_sid=576df78bc&_ss=r&nb_platform=shareasale

In today's episode, sponsored by Veeva, we'll hear a roundtable discussion on this fascinating topic featuring Victoria Serra Gittermann, European customer experience lead at Veeva Systems and Sebastian Noel, Veeva's director of multichannel strategy – moderating a discussion with two executives with first-hand experience leading this change: Andy Eeckhout, global head of CRM and digital solutions at Advanz Pharma and Mokhtar Elsayed, head of global go to market commercial transformation at Sanofi.  

Veeva Systems Inc., Q2 2024 Earnings Call, Aug 30, 2023

Unlike an electrical engineer or a plumber, clinical research roles are not explicitly defined or categorized as such, in government employment databases. There are no certification or degree requirements to work as a clinical research professional either. To explore the topic of clinical research as a profession, I invited Erike Stevens on the podcast. Erika advises life sciences, academic medical centers, hospitals, cancer centers, foundations and health systems process improvement initiatives for productivity, quality and efficiency in operations, cross-functional relationships, administration, manufacturing, and compliance.  She has over 20 years of research/ R&D experience, serving in roles such as Vice President Research, Senior Managing Director, Director Clinical Trials Office, Director of Clinical Research, Interim Executive Director, Clinical Trials Office and Director of Research Operations.  Erika holds her B.A. from the University of Vermont, her M.A. from Case Western Reserve University and her M.A. from Temple University.  She also holds a Graduate Certificate in Gerontology from Case Western University. Please join me in welcoming Erika on the show. Podcast Sponsor(s): This podcast is brought to you by Slope. Slope drives operational excellence for highly complex, sample-intensive, early-phase clinical trials. The platform transforms chaotic clinical trial supply chains into protocol-specific operational workflows for sponsors, CROs, clinical research sites and labs. Slope is trusted by industry leaders in complex early-phase clinical trials from top 50 pharma and CROs to emerging biotechs, and a global site network including NCI cancer centers and AMCs. Learn more at https://www.slopeclinical.com/ This podcast is brought to you by Veeva. Veeva connects patients, sites, and sponsors, on a single technology ecosystem to make clinical trials easier and faster. I'm particularly excited about Veeva SiteVault. SiteVault gives research sites one place to work with sponsors – to reduce the number of systems and logins used to run clinical trials. To learn more, visit https://sites.veeva.com/.  

To learn about community engagement in clinical trials, what it means, recent regulations and guidance documents, I invited Chris Komelasky, CEO and Co-founder of SiteBridge Research, on the podcast.  SiteBridge Research is an Integrated Research Organization (IRO). Chris and his team help connect physicians and their patients to clinical trials and facilitate the process by reducing barriers for sites and participants. Prior to the launch of SiteBridge, Chris has held various leadership roles at PPD, GlaxoSmithKline, Accenture and ZS Associates. Chris holds a B.S. in Systems Engineering from the University of Virginia and an MBA from Duke University and resides with his wife and three children in Chapel Hill, NC. Please join me in welcoming Chris on the Clinical Trial Podcast. Sponsors: This podcast is brought to you by Slope. Slope drives operational excellence for highly complex, sample-intensive, early-phase clinical trials. The platform transforms chaotic clinical trial supply chains into protocol-specific operational workflows for sponsors, CROs, clinical research sites and labs. Learn more at https://www.slopeclinical.com/ This podcast is brought to you by Veeva. Veeva connects patients, sites, and sponsors, on a single technology ecosystem to make clinical trials easier and faster. I'm particularly excited about Veeva SiteVault. SiteVault gives research sites one place to work with sponsors - to reduce the number of systems and logins used to run clinical trials. To learn more, visit https://sites.veeva.com/.

Veeva Systems Inc., Q1 2024 Earnings Call, May 31, 2023

Recently attending the Veeva R&D and Quality Summit in Madrid, pharmaphorum web editor Nicole Raleigh sat down with Veeva's president of Europe, Chris Moore. The event seen as a chance to bring the whole industry together, Moore explained how there is an excitement in the industry currently, with more drugs being developed, more conditions being treated – including those not before addressed – and that Veeva is endeavouring to do what it can to help raise the industry capabilities. So it is that the event has become a test bed to see whether the company is on the right track.

Pip offenbart endlich seine größte Schwäche. Apple's One More Thing ist eine Uhr für den Nachttisch (und eine 3500$ Apple Vision Pro Skibrille). Robert Kennedy Jr. sieht die Schuld für Amokläufe bei Antidepressiva statt bei Waffen. Es gibt Earnings von DigitalOcean, Hims & Hers, Veeva, MongoDB und GitLab. Philipp Glöckler (https://www.linkedin.com/in/philippgloeckler/) und Philipp Klöckner (https://twitter.com/pip_net) sprechen heute über: (00:00:00) Böhmermann, Twitter, Elon, Kennedy (00:12:30) Apple WWDC (00:44:50) DigitalOcean (00:45:15) Hims & Hers  (00:53:40) Veeva Systems (00:57:50) MongoDB (00:59:50) GitLab (01:02:15) Amazon Phone (01:07:20) TikTok Suche Shownotes: Werbung: Philipp Gloeckler hat Marissa und Marc am Braze Stand der OMR besucht und einen Podcast aufgenommen. Sie sprechen über OMR, Customer Engagement, die steigende Relevanz von AI und natürlich Pickleball. Den Podcast kannst du jetzt auf braze.com/warum-braze hören. Robert Kennedy Jr., With Musk, Pushes Right-Wing Ideas and Misinformation: https://www.nytimes.com/2023/06/05/us/politics/robert-f-kennedy-jr-twitter-2024.html SEC Binance: https://twitter.com/adamscochran/status/1665744500176879616?s=46&t=Pu5bpsIscUYNQg1GlyP7Vw Amazon: https://www.theverge.com/2023/6/2/23746605/amazon-prime-wireless-mvno-report-phone-service Doppelgänger Tech Talk Podcast Sheet https://doppelgaenger.io/sheet/ Disclaimer https://www.doppelgaenger.io/disclaimer/ Passionfroot Storefront www.passionfroot.xyz/doppelgaenger Post Production by Jan Wagener https://www.linkedin.com/in/jan-wagener-49270018b/ Aktuelle Doppelgänger Werbepartner https://lollipod.de/sn/doppelgaenger-werbung

Das Buch zum Podcast? JETZT vorbestellen. Lieber als Newsletter? Geht auch. Amazon wird zur Telekom. Die Telekom hasst es. Sentinel One hasst die eigene Prognose. Alles andere als Hass gab's für die Prognosen von Lululemon & MongoDB. Außerdem: Schuldengrenze weg, Jobs da. Momentum ist der Rückenwind der Börse. Aber was hoch fliegt, kann auch tief fallen und Totgesagte leben länger. Also: Machen Momentum-ETFs eigentlich Sinn? (WKN: A1W1K6). Was haben BASF, Pfizer & Unilever gemeinsam? Sie sind Kunden von Veeva Systems (WKN: A1W5SA). Was haben Veeva Systems und Microsoft gemeinsam? Sie gehören zu den 30 wertvollsten Software-Firmen der Welt. Diesen Podcast vom 05.06.2023, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. Learn more about your ad choices. Visit megaphone.fm/adchoices

Throughout his career, Dan Goldsmith has focused on how the application of technology can change the world. His work in life sciences, education, and healthcare has allowed Dan to make an impact on a global scale and gain insights from hundreds of organizations. Dan is currently CEO of Tendo, a software company focused on seamlessly connecting patients, clinicians, and caregivers throughout the care cycle. Prior to Tendo, Dan was the CEO of Instructure, supporting the teaching and learning needs of more than 30 million students and teachers using Canvas. Dan also spent 8+ years at Veeva where, as Chief Strategy Officer, he helped the company IPO and become the leading software provider to the life sciences industry. Earlier in his career, Dan held senior executive roles at Accenture, PriceWaterhouseCoopers, and IBM. Dan is an active advisor, investor, board member, and philanthropist. His service spans public, private, and non-profit organizations. Dan graduated from the University of Rochester and currently resides in the Philadelphia area, but he can often be found on the Silicon Slopes of Utah or working with organizations in Silicon Valley.Connect with Behind Company Lines and HireOtter Website Facebook Twitter LinkedIn:Behind Company LinesHireOtter Instagram Buzzsprout

Community health system-based research continues to become an important focus area for pharmaceutical and medical device sponsors given the recent FDA guidance on diversity in clinical trials.  Our guest for this episode is JoAnne Levy, Vice President at Mercy Research, a part of Mercyhealth.  Mercy Research is one of the largest fully integrated, community health system-based research organizations in the United States with more than 40 acute care, managed, and specialty hospitals, convenient urgent care locations, imaging centers and pharmacies. In 2022, over 38,000 Mercy patients contributed to research learning. JoAnne has served in the healthcare industry for almost 30 years. She leads Mercy Research, a not-for-profit organization managing clinical and real-world-evidence research activities across Mercy. JoAnne serves as current Chair and inaugural founder of Mercy Women in Leadership Council and as a member of Mercy's Diversity, Equity, Inclusion and Belonging Advisory Board. JoAnne received her undergraduate, law and master of business administration degrees — all with honors — from Washington University in St. Louis.  Please join me in welcoming JoAnne on the Clinical Trial Podcast.  This podcast is brought to you by Veeva. Veeva connects patients, sites, and sponsors, on a single technology ecosystem to make clinical trials easier and faster. I'm particularly excited about Veeva SiteVault. SiteVault gives research sites one place to work with sponsors - to reduce the number of systems and logins used to run clinical trials. To learn more, visit https://sites.veeva.com/. This podcast is brought to you by Slope. Slope drives operational excellence for highly complex, sample-intensive, early-phase clinical trials. The platform transforms chaotic clinical trial supply chains into protocol-specific operational workflows for sponsors, CROs, clinical research sites and labs. Learn more at slopeclinical.com  

Amanda Santimaw is the Director of Clinical Research for the 9 locations of Arizona Arthritis & Rheumatology, plus 4 external physician locations. She is responsible for the oversight of over 180 current clinical trials, 17 Principal Investigators, 24 dedicated research staff working in rheumatology, gastroenterology, endocrinology, and internal medicine. She has 15 years of experience working in Phase I-IV clinical trials, observational studies, and retrospective data analysis. Amanda received both her Bachelors of Science and Masters of Science in Clinical Research Management from Arizona State University. When Amanda is not at work, she enjoys spending time with her husband, daughter and new baby, going hiking, camping, and traveling Rebecca Martinez is the Operations Manager of Clinical Research and is Amanda's co-pilot for all the locations. She has over 10 years' experience in the clinical research field in rheumatology and gastroenterology.  She is responsible for the successful study start-up, recruitment, and maintenance for all the ongoing trials. She too received her masters of science in clinical research management from ASU. This week we discuss the challenges of managing site level documents, making the jump to electronic regulatory with Veeva, CTMS, eSource and so much more.

Jake Saper is a General Partner at Emergence Capital, one of the best SaaS VCs in the world. They've invested in iconic companies such as Salesforce, Zoom, Veeva, Gusto, Box, and Bill.com. He was previously at Kleiner Perkins as part of their Green Growth Fund and has an MBA from Stanford. In this episode, we cover a range of topics including: - Limitations of generative AI in B2B SaaS - Iterative AI vs Generative AI - How to solve the user engagement problem with AI - Coaching networks - Pricing model for AI companies - How to build a moat - How you invest in startups - GTM motion of successful AI companies - AI market trends Jake's favorite book: Freedom at Midnight (Authors: Larry Collins and Dominique Lapierre) --------Where to find Prateek Joshi: Newsletter: https://prateekjoshi.substack.com Website: https://prateekj.com LinkedIn: https://www.linkedin.com/in/prateek-joshi-91047b19 Twitter: https://twitter.com/prateekvjoshi 

Alessandro Maoggi, Senior Manager of Engineering at Veeva Systems, shares their journey and lessons learnt developing AI/ML tools with AWS Sagemaker.Topics Include:Intro to Veeva SystemsBackground of Veeva TMF BotLeveraging AWS SageMakerScaling horizontally with smaller instances

Veeva Systems Inc., Q4 2023 Earnings Call, Mar 01, 2023

Contract Research Organisations (CROs) are a vital cog in the pharmaceutical industry – they provide essential support services to help companies conduct clinical research more efficiently and effectively, saving money and time. Whilst CROs traditionally largely involve data management, new technological advancements are changing how they work. Richard Young, Vice President Vault CDMS Strategy at Veeva Systems, joins me on Tech Talks Daily to explore how study teams can now aim higher because of new technologies, as they can begin to work faster and more efficiently, and traditional CROs can use technology to help them look at data with fresh perspectives, as automation helps with the bulk of data management. We also talk about how new technology means that there is no longer the burden of tedious administrative tasks that took up workers' time. Workers can use platforms like Veeva's to sort data efficiently, allowing them to be able to focus on important data analysis instead. In turn, this will enable better clinical data success. Employees could therefore benefit from upskilling, rather than necessarily being replaced by technology.

There are advantages and disadvantages when it comes to being a standalone clinical trial site.  Standalone clinical trial sites enjoy the freedom of running their own operations. But they may face challenges with executing some parts of a clinical trial.  This is where site networks come in.  For example, a site can run more efficient marketing campaigns, be more systematic in its clinical trial operations, or share patient recruitment and retention resources by being part of a site network. To learn more about site networks, I invited Christian Burns, President of Elligo Health Research and Co-Founder of ClinX, on the show. Christian is a serial entrepreneur, investor, and founder of multiple clinical trial companies, including ClinEdge, BTC Network, and Guidestar Research.  Christian has a track record of success in the pharmaceutical industry, with a particular focus on decentralized and direct-to-patient clinical trials.  With experience across most therapeutic areas and a presence in over 30 languages and 40 countries, Christian's companies have served patients and providers across thousands of research sites globally.  His goal is to accelerate the development of new therapies by creating innovative solutions that connect and empower the clinical trial ecosystem.  A native of Philadelphia, Christian holds a B.A. in Public Health from the University of Tampa. Enjoy! Sponsors: This podcast is brought to you by Veeva. Veeva connects patients, sites, and sponsors, on a single technology ecosystem to make clinical trials easier and faster. I'm particularly excited about Veeva SiteVault. SiteVault gives research sites one place to work with sponsors - to reduce the number of systems and logins used to run clinical trials. To learn more, visit https://sites.veeva.com/. This podcast is brought to you by Slope. Slope's eClinical Supply Chain Management (eCSCM) platform reduces clinical trial risks, reigns in costs, improves the productivity of clinical trial collaborators, and increases subject retention by removing the manual, spreadsheet-driven, and error-prone processes used to manage and track clinical supplies and biological samples to a digital platform. To learn more, visit slope.io.   

In this episode, I'm excited for you to learn about Heart Failure Clinical Trials for medical devices. Our guest today is Sonna Patel-Raman. Sonna is currently the President at NuPulse Inc, an early stage medical device company responsible for developing the first minimally invasive, long-term, ambulatory counterpulsation device that works in sync with the heart. At NuPulse, Sonna is responsible for developing and executing on strategic initiatives for the company, building a diverse and multidisciplinary team of engineers, regulatory and quality associates, marketing, manufacturing, clinical affairs and education, and trial operations. Sonna and her team successfully completed enrollment in an FDA-approved feasibility trial and are now working towards the next phase of their medical product development lifecycle. Sonna has extensive experience in the heart failure medical device space. Prior to joining NuPulse in 2015, she worked as the FDA Branch Chief where she managed a team of 16+ reviewers and clinicians and was responsible for the technical review and development of pre-marketing approvals (PMAs), Investigational Device Exemption (IDEs), 510k)s and more. In this interview, Sonna provides us with a great introduction to heart failure trials, an overview of the medical device ecosystem for the treatment of heart failure, unique operational considerations for heart failure clinical trials, working as a woman leader in the medtech space, and more. Sonna is an effective communicator (as you'll soon find out after listening to this interview) and an amazing human being. I hope you enjoy my conversation with Sonna Patel-Raman.  Sponsors: This podcast is brought to you by Veeva. Veeva connects patients, sites, and sponsors, on a single technology ecosystem to make clinical trials easier and faster. I'm particularly excited about Veeva SiteVault. SiteVault gives research sites one place to work with sponsors - to reduce the number of systems and logins used to run clinical trials. To learn more, visit https://sites.veeva.com/. This podcast is brought to you by Slope. Slope's eClinical Supply Chain Management (eCSCM) platform reduces clinical trial risks, reigns in costs, improves the productivity of clinical trial collaborators, and increases subject retention by removing the manual, spreadsheet-driven, and error-prone processes used to manage and track clinical supplies and biological samples to a digital platform. To learn more, visit slope.io. 

Sehen wir uns um 21 Uhr auf der Doppelgänger Weihnachtsfeier auf Twitch? Pip möchte nur 8 Minuten über Elon reden und Philipp hat sich den Sion von Sono Motors angeschaut. Welche Gehaltsrange kann man als Founders Associate erwarten? Wie sehen die Zahlen von Veeva Systems aus? Philipp Glöckler (https://www.linkedin.com/in/philippgloeckler/) und Philipp Klöckner (https://twitter.com/pip_net) sprechen heute über: (00:00:30) Weihnachtsfeier auf Twitch (00:03:39) Elon (00:25:00) Sono Motors (00:43:00) Econos (00:44:10) Founders Associate (00:48:40) Veeva Shownotes: twitter = publisher: https://twitter.com/elonmusk/status/1604588904828600320 Linketree: https://twitter.com/banditelli/status/1604537880482762752 System Walls: https://twitter.com/drewblagrim/status/1604551253090074627 Besserung gelobt: https://twitter.com/elonmusk/status/1604616863673208832 Washington Post Artikel: https://www.washingtonpost.com/technology/2022/12/18/details-of-musk-stalking-incident/ Elon in SF https://twitter.com/elonmusk/status/1600902278927380480 Sono Punkte Video https://www.youtube.com/watch?v=8pcdMpwLyK4 **Doppelgänger Tech Talk Podcast** Weihnachtsfeier am 21. Dez. ab 21 Uhr Twitch https://www.twitch.tv/doppelgaengerio Sheet https://doppelgaenger.io/sheet/ Earnings & Event Kalender https://www.doppelgaenger.io/kalender/ Disclaimer https://www.doppelgaenger.io/disclaimer/ Passionfroot Storefront www.passionfroot.xyz/doppelgaenger Post Production by Jan Wagener https://twitter.com/JanAusDemOff Aktuelle Doppelgänger Werbepartner https://lollipod.de/sn/doppelgaenger-werbung

Jasmyn's LinkedIn: https://www.linkedin.com/in/jasmynadams/Veeva Site Vault: https://sites.veeva.com/The University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/Text Me: (949) 415-6256My podcast is Random Musings From The Clinical Trials GuruListen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/dp/1090349521/...Text "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe Clinical Research Circle: https://www.youtube.com/channel/UCgOSm8EN_M7xf9Xfw1m778wMy TikTok: DanSferaTimestamps:Jasmyn's introduction to this episode. 0:00How to use Veeva's site as a lead sponsor. 2:12When did you first decide that you wanted to have a health care career? 7:28What does equity mean in a capitalistic society? 12:57What do you do when you feel like your career is in danger? 18:52There's always opportunities for everyone in every industry. 21:14Jobhopping as a career growth tool. 25:45What are the trainings that are required? 31:19It benefits big corporations to be unknown and a commodity so you don't get opportunities. 37:58The closer you are to the decision maker, the better you will be for yourself as a worker. 43:50What prompted the creation of the podcast. 46:31You don't need to go back to school to get your degree. 53:25What do you teach in your core for Career Coaching? 59:48Why women don't ask for what they want. 1:06:53

Veeva Systems Inc., Q3 2023 Earnings Call, Dec 01, 2022

Veeva Site Vault: https://sites.veeva.com/Bree's LinkedIn: https://www.linkedin.com/in/bree-burks-78a26040/SiteVault training is available here https://sites.veevavault.help/gr/resources/training-resources/ and on YouTube https://youtube.com/c/VeevaSiteVaultThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/Text Me: (949) 415-6256My podcast is Random Musings From The Clinical Trials GuruListen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/dp/1090349521/...Text "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe Clinical Research Circle: https://www.youtube.com/channel/UCgOSm8EN_M7xf9Xfw1m778wMy TikTok: DanSferaTIMESTAMPS:0:00 Why do more nurses not know about research?3:09 Why do you think there's a young people exodus from academia?8:30 Why more nurses don't know about research in healthcare.11:04 How did you get into the field of research?17:50 How can we get free Veeva training?24:54 Academia is a trap.27:15 What's the main crux of the article?33:33 Do you have any leads for Director of Clinical Ops in Dallas?36:24 Can you still use SIP? What is it?41:53 What's the worst they can say if you don't apply?48:13 Who's going to plug their EHR into your system when it has nothing to do with research?50:13 EHR is like a treasure trove they want to publish on it all.57:08 How to transition from an international coordinator to a CRC in the US.

Analyst/Investor Day -Veeva Systems Inc

In today's episode of How We Got There (which was recorded earlier this year, before the downturn), I talk with Doug Landis, who is a Growth Partner at Emergence Capital. Doug spent some time at Salesforce and Box before moving into his current role in helping Emergence's portfolio companies with go-to-market assistance. He was working in the early days of sales enablement and now recommends hiring rev ops and sales enablement roles earlier than you think, even at Series A, to drive productivity in the sales organization. Emergence Capital is a venture capital firm that invests in B2B Enterprise SaaS businesses for their Series A and B funding rounds. They've invested in Veeva, Steelbrick, Box, and many more household names in the Salesforce ecosystem. The biggest challenge every early stage company will face is pipeline and that can be helped by hiring Marketing leadership before sales leadership, because sales professionals won't enjoy being full cycle for very long. His message to early stage founders is to become obsessed with pipeline. In deals over $10k, there are normally 8-10 people in the buying decision even if there is a single major person that your solution will help. A good benchmark for any AE is they should be generating ~20% of their own pipeline. Key metrics to look at are by account, how many contacts are on each account and then dive deeper into touches by contact to know depth of engagement in a given opportunity. Looking at conversion rates can help you zero in on gtm priorities to work on. Technical founders make mistakes by hiring a salesperson too early because you need to learn how to sell early on. A good target is for you to sell the first $1M in ARR and collect insane insights along the way for your product while capturing referrals. Hiring customer success people early on the other hand is wise because your first few customers need to be successful, you can't afford to churn your first customers (unless you learn they aren't a good fit for where you're going). Before starting the process of fundraising, you need to know your data inside and out beyond your pitch deck that includes a strong “why”. Include customer stories to help tell your story. It's important to make a thoughtful list of potential investors that will be good long-term partners with you who will offer you the right level of engagement to guide you on the things you might be missing. For the ecosystem specific advice, he shares a word of caution for ISVs in getting Salesforce Ventures to participate in your round. Doug's view is when you take Salesforce Ventures money…..and it's cause for pause. If they build something like what you're offering, you could be in big trouble. He share the story of Steelbrick (Emergence was the lead investor here) and Apttus and how Salesforce leveraged their relationship to strong arm Steelbrick during the acquisition. Here's a closer look at the episode: 1:37 How did you find your way into the ecosystem? 5:13 Sales enablement 9:55 Who is Emergence and what's your role there? 14:16 What are some elements that make a great go to market approach in a series A or B company? 22:07 What's the biggest mistake you see technical founders make before they hire professional salespeople? 25:53 So founders in the ecosystem, if they're considering raising institutional capital, what should they know before starting the process? 34:15 What are you most proud of in your career? 36:10 The final three Doug's Linkedin: https://www.linkedin.com/in/douglandis/ Emergence Capital's Website: https://www.emcap.com/ Emergence Capital's Linkedin: https://www.linkedin.com/company/emergence-capital-partners/

Q2 earnings season has delivered many surprises on the one hand and continuations of trends on the other hand. For SaaS companies, that has meant continued drifting. Last week, Okta, MDB, and Veeva reported, and we break down each of those companies on this week's the Razor's Edge (you can also read Akram's take here). We get into the challenges each of those companies face, but also the broader difference between "legacy" SaaS companies like Salesforce and the newer all cloud products like Okta. Topics Covered 2:30 minute mark - Okta's earnings – what went wrong and what differentiates the Oktas from the Salesforces 10:00 – The value of “the suits” and the challenge of building a microservice-based business model 23:00 – The presumption that software is a great model 28:00 – MDB's earnings 40:00 – Cutting to profitability amidst the tech recession 52:00 – The consolidation calvary is not about to arrive, and what else to watch 58:00 – Notes on Veeva 1:04:00 – Docusign preview

Veeva Systems Inc., Q2 2023 Earnings Call, Aug 31, 2022

We sit down with the CEO founders of two of the most capital efficient success stories of all time — Zoom and Veeva Systems — to understand how they grew to billions of dollars in revenue (and tens of billions in market cap) on very, very little capital invested. With the fundraising environment changing rapidly, we couldn't think of a better topic to discuss or better sources of wisdom for founders, operators and investors all to learn from. Very special thanks to Jake Saper and our friends at Emergence Capital for inviting us and putting this conversation together at their 2022 CEO Summit! This episode has video! You can watch it on Spotify (right in the main podcast interface) or on YouTube. Links: Peter's great Medium blog Sponsors: Thanks to the Solana Foundation for being our presenting sponsor for this special episode. Solana is the world's most performant blockchain, the BEST place for developers to build Web3 applications, and of course very near & dear to the Acquired community's heart. You get in touch with them here, and learn more about GenesysGo here. Just tell them them at Ben and David sent you! Thank you as well to Modern Treasury and to Mystery. ‍Note: Acquired hosts and guests may hold assets discussed in this episode. This podcast is not investment advice, and is intended for informational and entertainment purposes only. You should do your own research and make your own independent decisions when considering any financial transactions.

We sit down with the CEO founders of two of the most capital efficient success stories of all time — Zoom and Veeva Systems — to understand how they grew to billions of dollars in revenue (and tens of billions in market cap) on very, very little capital invested. With the fundraising environment changing rapidly, we couldn't think of a better topic to discuss or better sources of wisdom for founders, operators and investors all to learn from. Very special thanks to Jake Saper and our friends at Emergence Capital for inviting us and putting this conversation together at their 2022 CEO Summit!Sponsor: https://acquired.fm/zoominfoThis episode has video! You can watch it on YouTube.Links:Peter's great Medium blog‍Note: Acquired hosts and guests may hold assets discussed in this episode. This podcast is not investment advice, and is intended for informational and entertainment purposes only. You should do your own research and make your own independent decisions when considering any financial transactions.